V-Wave develops a minimally invasive implanted shunt device for treating patients with severe heart failure. Once implanted, the device can help control elevated left atrial pressure, the primary cause of breathing difficulty and hospitalization due to heart failure, V-Wave said. The company received approval from the U.S. #FoodandDrugsAdministration to launch an investigational device exemption study, and has launched a global clinical trial, the company said.

With this funding, #V-Wave CEO Neal Eigler said in a statement, “we can pursue the science that will bring us a giant step closer to commercial release of an easy to $implantdevice that can provide the hope for immediate and longer-term symptom relief, increased exercise capacity, decreased need for acute hospital admission, and reduced mortality with an improved quality of life for hundreds of thousands of suffering patients.”